An Observational, Prospective, Multicenter, Open-label Study to Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

NCT07570589 | Not Yet Recruiting

• 1 other identifier: 25-PP-23
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Generalized Myasthenia Gravis (gMG) is a rare autoimmune disease (a disease in which the body attacks its own tissues) that causes muscle weakness and significant fatigue. Current treatments (corticosteroids, plasma exchange, intravenous immunoglobulin infusions) improve symptoms in many patients. However, many continue to suffer from fatigue and fatigability that are not well measured by standard tools. Moreover, these treatments can cause significant long-term side effects, reducing quality of life. New treatments such as Rozanolixizumab (ROZ) are now available. They act rapidly and are well tolerated, allowing better symptom control while reducing the risks associated with conventional treatments. To properly evaluate these new treatments, it is essential to understand patients' perspectives on their effectiveness. The scales used by physicians do not always capture all the symptoms experienced by patients, particularly fatigability. This is why a new tool has been developed: the MG symptoms PRO. This questionnaire allows patients to assess their own symptoms (fatigue, weakness of the eyes, mouth, breathing, muscle fatigability) in detail. This research aims to better understand the effectiveness of treatments from the patients' perspective in order to improve their care. The goal of the study is to evaluate the impact of Rozanolixizumab administration in real-world practice through the MG symptoms PRO questionnaire. This is an observational study, meaning that the medication is prescribed by the physician according to current regulations, and the study simply collects routine medical data during your follow-up, over a period of approximately 9 months.

Conditions

Generalized Myasthenia Gravis

Outcome Measures

Primary Outcomes (1)

• To assess in real-life the impact of the ROZ on MG symptoms PRO score in generalized MG patients with anti-AChR or anti-MUSK antibodies

  To monitor 7 days after the end of every cycle of treatment for 9 months the change from baseline of MG symptoms PRO score.

  7 days after the end of every cycle of treatment for 9 months

Secondary Outcomes (4)

• Evaluate the impact of real life on MG symptoms PRO global sub-scores physical fatigue

  7 days after the end of every cycle of treatment for 9 months

• Evaluate the impact of real life on quality of life measured by MG-QOL15r

  7 days after the end of every cycle of treatment for 9 months

• Evaluate the impact of real life on patient general state, measured by the Patient-Acceptable Symptom State (PASS)

  7 days after the end of every cycle of treatment for 9 months

• Evaluate the impact of real life on the evolution of gMG after each cycle measured by MG-ADL score

  7 days after the end of every cycle of treatment for 9 months

Interventions

Patients diagnosed with generalized myasthenia gravis and treated with Rozanolixizumab OTHER

Patients are evaluated using the MG Symptoms PRO questionnaire

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients affected by generalized Myasthenia Gravis with anti-AChR and anti-MUSK and treated with ROZ

You may qualify if:

• Male or female subjects aged ≥18 years;
• Diagnosed with MG with confirmed documentation and supported by a physical exam and confirmed seropositivity for anti AChR or anti MUSK antibodies;
• Meets the clinical criteria as defined by the Myasthenia Gravis Foundation of America (MFGA) for generalized MG class IIa, IIb, IIIa, and IIIb;
• Patient suitable for ROZ treatment (IgG ≥ 5,5 g/l);
• MG-ADL score ≥ 3 (with ≥ 3 points of non-ocular symptoms);
• Patient must have received all mandatory vaccinations according to local regulations prior to study enrollment;
• Capable of understanding the written informed consent, and providing signed, dated, and witnessed written informed consent;
• Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures;
• Patient affiliated to a European social security system.

You may not qualify if:

• Any current mental condition (psychiatric disorder, senility, or dementia) that, in the opinion of the investigator, may affect study compliance or prevent understanding of the aims, investigational procedures, or possible consequences of the study; and/or patient with a Mini-mental State evaluation (MMSE) of \<25;
• History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject;
• History of ongoing malignancy (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured);
• Patient receiving concomitant treatment with rituximab, anti-FcRn, complement inhibitors and/or PLEX;
• Patients discontinued from rituximab without respecting the administration rules of ROZ;
• Patient with end-stage diseases or with a disease that will enable him to be evaluated and/or treated;
• Patients with non-treated active infections;
• Patients with hypersensitivity to the active substance(s) or to any of the excipients, specifically: histidine, histidine hydrochloride monohydrate, proline, polysorbate 80, or water for injections.
• Subject, or close relative of the subject, is the investigator or a sub-investigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site;
• Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nice: lead

Study Sites (1)

CHU de NICE

Nice, Alpes-maritimes, 06000, France

Location

MeSH Terms

Conditions

Myasthenia Gravis

Interventions

Therapeutics; rozanolixizumab

Condition Hierarchy (Ancestors)

Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Junction Diseases; Neuromuscular Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 30, 2026
• First Posted: May 6, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): March 1, 2028
• Study Completion (Estimated): March 1, 2028
• Last Updated: May 6, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)